On August 12, 2026, InterCure Ltd. entered into a securities purchase agreement for a private placement offering of 1,579,028 units at $2.918 per unit. Each unit consists of one ordinary share and one warrant exercisable at $1.59 per share for five years. The offering was completed on August 25, 2026, generating gross proceeds of approximately $5 million from non-affiliated investors, with an additional expected $2 million from CEO Alexander Rabinovich, whose participation requires shareholder approval. Proceeds will fund working capital and rehabilitate the Nir Oz facility of subsidiary Canndoc Ltd. InterCure Ltd. operates in the cannabis industry, developing and distributing medical marijuana products.
